COMP360 Phase 3 Shows ~4-Point MADRS Gain; Rollout Targets 8,500 SPRAVATO Sites
CMPS has more than doubled off its 52-week low of $4.82.
Summary
New Phase 3 data for COMP360 in treatment-resistant depression shows a ~4-point MADRS improvement over placebo, with ~25% of patients responding after one dose and ~40% after two doses three weeks apart. Effects were durable out to 26–52 weeks. The company plans two initial doses at least three weeks apart, with physicians deciding on additional dosing, and expects 2–4 annual doses per patient. Commercial strategy targets ~8,500 existing SPRAVATO sites and includes reimbursement support. This adds specific efficacy and rollout details to the positive trial results reported in July and September, strengthening the case for regulatory submission and market adoption.
At the time of this announcement, CMPS was trading at $14.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $4.82 to $15.87. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.